102 related articles for article (PubMed ID: 6761807)
21. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
Lecrubier C; Girard P; Noire P; Samama M
Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
[No Abstract] [Full Text] [Related]
22. [Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
Avellone G; Mandalà V; Novo S; Pinto A; Riolo FP; Davì G; Raneli G
Boll Soc Ital Cardiol; 1981; 26(8):697-712. PubMed ID: 6289854
[No Abstract] [Full Text] [Related]
23. [Platelet aggregation inhibitors].
Castaigne A; Benghozi R; Bienvenu MP
Rev Infirm; 1981 Dec; 31(19):45-8. PubMed ID: 6977177
[No Abstract] [Full Text] [Related]
24. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
Picard-Fraire C
Agents Actions Suppl; 1984; 15():68-75. PubMed ID: 6385655
[No Abstract] [Full Text] [Related]
25. The mechanisms of action of ticlopidine.
Bruno JJ
Thromb Res Suppl; 1983; 4():59-67. PubMed ID: 6356466
[No Abstract] [Full Text] [Related]
26. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
[No Abstract] [Full Text] [Related]
27. [Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
Thébault JJ; Blatrix C; Blanchard J; Panak E
Agressologie; 1983 Dec; 24(12):609-11. PubMed ID: 6670692
[No Abstract] [Full Text] [Related]
28. [Surveillance of treatment with antiaggregating agents].
Cauchie C
Rev Med Brux; 1983 Jan; 4(1):34-8. PubMed ID: 6340175
[No Abstract] [Full Text] [Related]
29. Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
Bono F; De Gasperi T; Zanelli P; Menta R; Castiglioni A; Savazzi GM; Cambi V
Farmaco Prat; 1983 Dec; 38(12):451-5. PubMed ID: 6662220
[No Abstract] [Full Text] [Related]
30. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
[TBL] [Abstract][Full Text] [Related]
31. [Function of prostaglandins in platelet aggregation].
Sun QW
Sheng Li Ke Xue Jin Zhan; 1980 Feb; 11(2):137-42. PubMed ID: 7001620
[No Abstract] [Full Text] [Related]
32. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide.
Han P; Boatwright C; Ardlie NG
Thromb Haemost; 1982 Apr; 47(2):150-3. PubMed ID: 7101234
[TBL] [Abstract][Full Text] [Related]
33. Effect of an inhibitor of TXA2 synthesis and of PGE2 on the formation of 12-L-hydroxy-5,8,10-heptadecatrienoic acid in human platelets.
Vincent JE; Zijlstra FJ; van Vliet H
Adv Prostaglandin Thromboxane Res; 1980; 6():463-6. PubMed ID: 7386279
[No Abstract] [Full Text] [Related]
34. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.
Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG
Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115
[TBL] [Abstract][Full Text] [Related]
35. [Changes in platelet aggregation during treatment with acetylsalicylic acid. Sensitivity of various aggregating agents].
Lecrubier C; Conard J; Horellou MH; Kher A; Samama M
Therapie; 1982; 37(5):581-6. PubMed ID: 7179328
[No Abstract] [Full Text] [Related]
36. [Stimulation of prostacyclin biosynthesis as a possible mechanism of action of dipyridamole (author's transl)].
Mentz P; Pönicke K; Block HU; Giessler C; Blass KE; Bayer BL; Förster W
Arzneimittelforschung; 1981; 31(12):2075-82. PubMed ID: 7037009
[TBL] [Abstract][Full Text] [Related]
37. [The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
Herman AG
Rev Med Brux; 1981 Mar; 2(3):251-7. PubMed ID: 7015444
[No Abstract] [Full Text] [Related]
38. Pinane thromboxane A2: a TXA2 antagonist with antithrombotic properties.
Aharony D; Smith JB; Smith EF; Lefer AM; Magolda RL; Nicolaou KD
Adv Prostaglandin Thromboxane Res; 1980; 6():489-92. PubMed ID: 6992538
[No Abstract] [Full Text] [Related]
39. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
40. [Influence of some vasoactive drugs on blood platelet aggregation].
Myśliwiec M; Bielawiec M
Pol Tyg Lek; 1971 Mar; 26(11):383-5. PubMed ID: 5550452
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
